MedPath

Testing and Evaluating the Collection of Patient Reported Outcomes In Cancer Care Using Innovative Approaches

Not Applicable
Not yet recruiting
Conditions
Cancer
Registration Number
NCT05911672
Lead Sponsor
Cyprus University of Technology
Brief Summary

Patient Reported Outcome Measures (PROMs) are patients' reports of their symptom experience, quality of life and functionality. These measures are used as an endpoint to clinical trials but rarely integrated into routine cancer care. Moreover, they are resource intensive and prone to retrospective biases. PRICE project aims to develop and evaluate a digital health tool (ePROM), collecting PROMs at the clinic and additional Ecological Momentary Assessment (EMA) of PROMs using a mobile application. In addition it tests whether patients who are identified to have elevated pain, fatigue, and stress will benefit from an Ecological Momentary Intervention (EMI) based on Virtual Reality environments. EMA can overcome biases and barriers in PROM assessment whilst EMI can offer an easy and possibly cost-effective intervention until patients re-visit the clinic. The project can contribute to monitoring patient data and achieve viable health systems. It is also timely since digital health tools are considered the future of oncology care but often lack robustness in development and evaluation. Patients treated for cancer at the German Oncology Centre in Cyprus will be randomized into three conditions: (a) Full Intervention (patients who are prompted to use the EMI based on their EMA data; (b) Partial Intervention (patients who are prompted to use the EMI irrespective of their EMA data); (c) Control (patients who only provide their EMA without an EMI). A dissemination strategy will ensure findings and innovation are available to the public, clinicians, students and policy-makers.

Detailed Description

Not available

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
90
Inclusion Criteria
  • Diagnosed with any type of cancer
  • Treated as either inpatient or outpatient
  • Good understanding of Greek
  • Able to consent
  • No psychiatric comorbidities
Exclusion Criteria
  • Diagnosed with psychiatric disorders
  • Unable to consent

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Change in usability and feasibility from baseline to one week laterBaseline, after treatment (1 week later)

System Usability and Feasibility questionnaire

Secondary Outcome Measures
NameTimeMethod
Anxiety using DASS-21Baseline, after treatment (1 week later)

DASS-21 anxiety scale with cut off scores: 0-7 normal, 8-9 mild, 10-14 moderate, 15-19 severe and 20+ extremely severe

EORTC QLQ-C-30Baseline, after treatment (1 week later)

Health-Related Quality of Life. Using the global quality of life scale (minimum 0, maximum 100), with higher scores indicating better outcome (higher quality of life)

Functionality using EQ-5D-5LBaseline, after treatment (1 week later)

EQ-5D-5L score is from 0-100 with higher scores indicating better outcome (higher functionality)

Fatigue Assessment Scale (FAS)Baseline, after treatment (1 week later)

Fatigue Assessment Scale with one score (minimum 10 maximum 50) with higher scores indicating worse outcome (higher fatigue)

Depression using DASS-21Baseline, after treatment (1 week later)

DASS-21 depression scale with cut off scores: 0-9 normal, 10-13 mild, 14-20 moderate, 21-27 severe and 28+ extremely severe

Stress using DASS-21Baseline, after treatment (1 week later)

DASS-21 stress scale with cut off scores: 0-14 normal, 15-18 mild, 19-25 moderate, 26-33 severe and 34+ extremely severe

Trial Locations

Locations (1)

Cyprus University of Technology

🇨🇾

Limassol, Cyprus

Cyprus University of Technology
🇨🇾Limassol, Cyprus
Angelos Kassianos, PhD
Contact
0035725002252
angelos.kassianos@cut.ac.cy
Andri Georgiou, MSc
Contact
antri_geor3@hotmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.